John J Crowley
CIK 1587972 · Chief Financial Officer · last filed 2026-06-24
John J Crowley is a Chief Financial Officer who has filed 21 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$185.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.58M
3
21
-$185.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief Financial Officer | 0 | $40.50 | $0 | $0 | 4 | 2026-06-24 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Chief Financial Officer | 0 | $21.55 | $0 | $110.5K | 7 | 2024-06-04 |
| CRL | SVP, Chief Accounting Officer | 5,599 | $282.00 | $1.58M | -$296.4K | 10 | 2016-10-04 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Disp (D) | −45,000 | $0 | EDGAR |
| 2026-02-03 | Centessa Pharmaceuticals plc (CNTA) Delisted | Grant (A) | +45,000 | $0 | EDGAR |
| 2025-02-04 | Centessa Pharmaceuticals plc (CNTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-07-02 | Centessa Pharmaceuticals plc (CNTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Disp (D) | −10,410 | $0 | EDGAR |
| 2024-01-05 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-09 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-03 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | +3,910 | $0 | EDGAR |
| 2021-02-08 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-07-02 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Buy (P) | +6,500 | $110.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.